Get started
NovaBay Pharmaceuticals, Inc.NovaBay Pharmaceuticals, Inc.NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

NBY chart


Full chart

NBY upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.39 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−35.4691 USD
Net income (FY)
‪−9.64 M‬ USD
Revenue (FY)
‪14.73 M‬ USD
Shares float
‪4.89 M‬
Beta (1Y)
2.93

Employees


Employees (FY)
26
Change (1Y)
−7 −21.21%
Revenue / Employee (1Y)
‪566.38 K‬ USD
Net income / Employee (1Y)
‪−370.77 K‬ USD

About NovaBay Pharmaceuticals, Inc.


Sector
Health Technology
CEO
Justin M. Hall
Headquarters
Emeryville
Website
novabay.com
Founded
2000
FIGI
BBG000PVPJT3
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

NBY news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of NBY is 0.6942 USD — it has decreased by −0.69% in the past 24 hours. Watch NovaBay Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange NovaBay Pharmaceuticals, Inc. stocks are traded under the ticker NBY.
NBY stock has fallen by −7.32% compared to the previous week, the month change is a −0.54% fall, over the last year NovaBay Pharmaceuticals, Inc. has showed a −94.01% decrease.
We've gathered analysts' opinions on NovaBay Pharmaceuticals, Inc. future price: according to them, NBY price has a max estimate of 8.00 USD and a min estimate of 6.60 USD. Watch NBY chart and read a more detailed NovaBay Pharmaceuticals, Inc. stock forecast: see what analysts think of NovaBay Pharmaceuticals, Inc. and suggest that you do with its stocks.
NBY reached its all-time high on Oct 26, 2007 with the price of 130,156.2500 USD, and its all-time low was 0.3611 USD and was reached on Aug 9, 2024. View more price dynamics on NBY chart.
See other stocks reaching their highest and lowest prices.
NBY stock is 12.50% volatile and has beta coefficient of 2.93. Track NovaBay Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is NovaBay Pharmaceuticals, Inc. there?
Today NovaBay Pharmaceuticals, Inc. has the market capitalization of ‪3.39 M‬, it has increased by 32.96% over the last week.
Yes, you can track NovaBay Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
NovaBay Pharmaceuticals, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
NBY earnings for the last quarter are −0.60 USD per share, whereas the estimation was −0.30 USD resulting in a −96.72% surprise. The estimated earnings for the next quarter are −0.19 USD per share. See more details about NovaBay Pharmaceuticals, Inc. earnings.
NovaBay Pharmaceuticals, Inc. revenue for the last quarter amounts to ‪2.44 M‬ USD, despite the estimated figure of ‪2.60 M‬ USD. In the next quarter, revenue is expected to reach ‪3.15 M‬ USD.
NBY net income for the last quarter is ‪−1.21 M‬ USD, while the quarter before that showed ‪−1.58 M‬ USD of net income which accounts for 23.53% change. Track more NovaBay Pharmaceuticals, Inc. financial stats to get the full picture.
No, NBY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 26.00 employees. See our rating of the largest employees — is NovaBay Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NovaBay Pharmaceuticals, Inc. EBITDA is ‪−4.40 M‬ USD, and current EBITDA margin is −32.60%. See more stats in NovaBay Pharmaceuticals, Inc. financial statements.
Like other stocks, NBY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NovaBay Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NovaBay Pharmaceuticals, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NovaBay Pharmaceuticals, Inc. stock shows the sell signal. See more of NovaBay Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.